Skip to main content
. 2015 Nov 19;5(11):e009241. doi: 10.1136/bmjopen-2015-009241

TableĀ 1.

Overview of patient participants and interviews conducted

Patient Aetiology DEPCAT MELD at recruitment Months in study Admissions during study involvement Interviews per time point (P=patient; C=carer; P&C=joint) Status at end of study
Male, 68 ALD 4 14 12 0 P&C1, P&C2, P&C3 Alive
Female, 38 ALD, HCV 5 20 12 3 P1, P2, P3, C1, C2, C3; GP Alive
Female, 66 AIH 4 20 5 5 P1, P2 Dead
Female, 60 ALD 5 17 7 6 P1, P2, C1, Bereavement; Consultant Dead
Female, 84 NAFLD 4 9 11 13 P1, P2, P3 Dead
Male, 74 HCC (NAFLD) 7 17 1 0 P1, Bereavement; GP Dead
Male, 77 ALD (NAFLD) 6 9 9 21 P1, P&C2, P&C3; GP; Palliative Care Nurse Dead
Male, 75 NAFLD 3 21 6 9 P1; GP Dead
Male, 35 ALD 4 24 12 5 P1, P2, P3, C1, C2; Alcohol Liaison Nurse Alive
Male, 58 ALD 5 13 6 7 P1 Dead
Female, 41 Cryptogenic 3 10 8 5 P&C1, P2, C2, P&C3; GP Alive
Female, 56 ALD, HCV 4 13 6 0 P1 Alive
Female, 45 ALD 3 16 7 2 P1, P2; GP Dead
Female, 68 NAFLD 3 15 5 9 P&C1, Bereavement; GP Dead
Female, 37 ALD 7 26 9 2 P&C1, P&C2, P&C3; GP Alive

(DEPCAT (Deprivation Category index): 1=least deprived; 7=most deprived).

AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; GP, general practitioner; HCC, hepato-cellular carcinoma; HCV, hepatitis C virus; MELD, Model of End-Stage Liver Disease; NAFLD, non-alcoholic fatty liver disease.